| AstraZeneca PLC | Precision Medicine Platforms | $294.1b | $168.24 | +0.5% | 4.0K | |
| Thermo Fisher Scientific, Inc. | Precision Medicine Platforms | $186.3b | $537.68 | 0.0% | 2 | |
| Danaher Corporation | Precision Medicine Platforms | $134.8b | $200.95 | 0.0% | 22 | |
| Vertex Pharmaceuticals Inc | Gene Therapy & Gene Editing | $126.1b | $477.37 | 0.0% | 27 | |
| Regeneron Pharmaceuticals Inc | Gene Therapy & Gene Editing | $65.4b | $649.11 | 0.0% | N/A | |
| Alnylam Pharmaceuticals, Inc. | RNA Therapeutics | $40.2b | $279.23 | 0.0% | 21 | |
| Natera, Inc. Common Stock | Genetic Testing & Diagnostics | $38.9b | $276.11 | 0.0% | 120 | |
| Waters Corp | Precision Medicine Platforms | $36.8b | $374.42 | 0.0% | N/A | |
| Illumina Inc | Genetic Testing & Diagnostics | $26.6b | $187.38 | 0.0% | 59 | |
| Insmed, Inc. | Gene Therapy & Gene Editing | $23.1b | $109.25 | 0.0% | 58 | |
| Labcorp Holdings Inc. | Genetic Testing & Diagnostics | $23.0b | $274.50 | 0.0% | N/A | |
| Guardant Health, Inc. Common Stock | Precision Medicine Platforms | $19.9b | $162.00 | 0.0% | 28 | |
| BridgeBio Pharma, Inc. Common Stock | Precision Medicine Platforms | $14.6b | $83.84 | 0.0% | N/A | |
| Ionis Pharmaceuticals, Inc. Common Stock | RNA Therapeutics | $13.1b | $55.84 | 0.0% | 25 | |
| Revvity, Inc. | Precision Medicine Platforms | $12.4b | $111.36 | 0.0% | 222 | |
| Arrowhead Research Corporation | RNA Therapeutics | $11.5b | $71.72 | 0.0% | 33 | |
| BioMarin Pharmaceuticals Inc | Gene Therapy & Gene Editing | $11.1b | $59.05 | 0.0% | N/A | |
| Bio-Techne Corp. | Precision Medicine Platforms | $11.0b | $71.48 | 0.0% | N/A | |
| Krystal Biotech, Inc. Common Stock | Gene Therapy & Gene Editing | $11.0b | $350.59 | 0.0% | N/A | |
| Tempus AI, Inc. Class A Common Stock | Precision Medicine Platforms | $10.4b | $56.50 | 0.0% | 9.2K | |
| Nuvalent, Inc. Class A Common Stock | Precision Medicine Platforms | $9.8b | $123.96 | 0.0% | N/A | |
| Kymera Therapeutics, Inc. Common Stock | Precision Medicine Platforms | $9.4b | $114.00 | 0.0% | 208 | |
| Praxis Precision Medicines, Inc. Common Stock | Precision Medicine Platforms | $9.3b | $327.55 | 0.0% | 57 | |
| QIAGEN N.V. | Genetic Testing & Diagnostics | $8.1b | $41.52 | 0.0% | 140 | |
| Lantheus Holdings, Inc | Precision Medicine Platforms | $7.2b | $104.30 | 0.0% | 495 | |
| Twist Bioscience Corporation Common Stock | Precision Medicine Platforms | $6.4b | $92.74 | 0.0% | 24 | |
| BillionToOne, Inc. Class A Common Stock | Genetic Testing & Diagnostics | $5.5b | $137.65 | 0.0% | 5 | |
| CRISPR Therapeutics AG | Gene Therapy & Gene Editing | $5.4b | $51.45 | 0.0% | 479 | |
| Caris Life Sciences, Inc. Common Stock | Precision Medicine Platforms | $5.0b | $17.64 | 0.0% | N/A | |
| 10x Genomics, Inc. Class A Common Stock | Genetic Testing & Diagnostics | $4.9b | $45.75 | 0.0% | 72 | |
| Veracyte, Inc. | Genetic Testing & Diagnostics | $4.7b | $59.59 | 0.0% | 2 | |
| Amicus Therapeutics, Inc | Gene Therapy & Gene Editing | $4.5b | $14.49 | +0.0% | 3.5M | |
| Dyne Therapeutics, Inc. Common Stock | Precision Medicine Platforms | $3.7b | $24.07 | 0.0% | 102 | |
| IDEAYA Biosciences, Inc. Common Stock | Precision Medicine Platforms | $3.6b | $36.25 | 0.0% | N/A | |
| Beam Therapeutics Inc. Common Stock | Gene Therapy & Gene Editing | $3.5b | $30.80 | 0.0% | 224 | |
| Adaptive Biotechnologies Corporation Common Stock | Precision Medicine Platforms | $3.4b | $22.93 | 0.0% | 978 | |
| uniQure N.V. | Gene Therapy & Gene Editing | $3.2b | $40.96 | 0.0% | 2.3K | |
| Intellia Therapeutics, Inc | Gene Therapy & Gene Editing | $2.4b | $12.96 | 0.0% | 8.2K | |
| Vericel Corporation | Gene Therapy & Gene Editing | $2.3b | $47.42 | 0.0% | 109 | |
| GeneDx Holdings Corp. Class A Common Stock | Precision Medicine PlatformsGenetic Testing & Diagnostics | $2.0b | $65.22 | 0.0% | 8 | |
| Precigen, Inc. Common Stock | Gene Therapy & Gene Editing | $2.0b | $5.09 | 0.0% | N/A | |
| Taysha Gene Therapies, Inc. Common Stock | Gene Therapy & Gene Editing | $2.0b | $6.15 | 0.0% | 2 | |
| NeoGenomics, Inc. | Genetic Testing & Diagnostics | $1.9b | $14.48 | 0.0% | N/A | |
| Sarepta Therapeutics,, Inc. Common Stock | Gene Therapy & Gene Editing | $1.9b | $17.52 | 0.0% | 91 | |
| Maze Therapeutics, Inc. Common Stock | Precision Medicine Platforms | $1.7b | $30.04 | 0.0% | N/A | |
| CareDx, Inc. | Genetic Testing & DiagnosticsPrecision Medicine Platforms | $1.5b | $29.80 | 0.0% | 971 | |
| Personalis, Inc. Common Stock | Genetic Testing & Diagnostics | $1.4b | $16.11 | 0.0% | 332 | |
| BioLife Solutions Inc. | Gene Therapy & Gene Editing | $1.4b | $28.65 | 0.0% | 104 | |
| MeiraGTx Holdings plc Ordinary Shares | Gene Therapy & Gene Editing | $1.3b | $12.57 | 0.0% | N/A | |
| Azenta, Inc. | Genetic Testing & Diagnostics | $1.2b | $26.71 | 0.0% | 2 |